Skip to main content
. 2022 Aug 5;13:911810. doi: 10.3389/fphar.2022.911810

TABLE 3.

Other subgroup analysis.

Outcomes Types of Invention Subgroup Heterogeneity Overall Effect Statistical method Studies(N) Participants (N) Figures
I2 (%) p MD 95%CI p Significance
DAS28-ESR-course IGU 12w 0 0.90 -0.14 [-0.25, -0.02] 0.02 Yes 2 113
24w 0 0.66 -0.36 [-0.65, -0.07] 0.01 Yes 2 120
Summary 0 0.54 -0.36 [-0.65, -0.07] 0.002 Yes Fixed 3 233 S13
IGU + MTX 12w 70 0.04 -1.04 [-1.63, -0.44] 0.0007 Yes 3 175
24w 91 <0.00001 -1.31 [-1.84, -0.79] <0.00001 Yes 6 703
52w 0 -0.89 [-1.21, -0.57] <0.00001 Yes 1 83
Summary 87 <0.00001 -1.18 [-1.48, -0.89] <0.00001 Yes Random 10 961 S14
ACR20-course IGU 52w 0 1.18 [1.06, 1.30] 0.002 Yes 1 590 S15
IGU + MTX 12w 0 0.40 1.48 [1.16, 1.91] 0.002 Yes 3 240
24w 48 0.11 1.23 [1.01, 1.49] 0.04 Yes 5 362
52w 0 1.17 [1.06, 1.30] 0.003 Yes 1 598
Summary 30 0.17 1.23 [1.10, 1.38] 0.0003 Yes Random 8 1200 S16
ACR50-course IGU + MTX 12w 0 0.86 1.91 [1.38, 2.64] <0.0001 Yes 3 240
24w 0 0.88 2.06 [1.60, 2.64] <0.00001 Yes 5 552
Summary 0 0.98 2.01 [1.64, 2.45] <0.00001 Yes Fixed 7 792 S17
ACR70-course IGU + MTX 12w 0 0.92 2.06 [1.30, 3.24] 0.002 Yes 2 140
24w 0 0.75 2.07 [1.28, 3.33] 0.003 Yes 6 452
Summary 0 0.94 2.06 [1.48, 2.88] <0.0001 Yes Random 6 592 S18
AEs-course IGU 24w 0 0.53 0.68 [0.44, 1.05] 0.08 No 2 140
52w 0 1.26 [0.77,2.06] 0.35 No 1 590
Summary 48 0.15 0.96 [0.71, 1.31] 0.80 No Fixed 3 730 S19
IGU + MTX 12w 15 0.32 0.72 [0.42,1.24] 0.23 No 4 290
24w 0 0.58 0.95 [0.76, 1.19] 0.66 No 12 1041
52w 20 0.28 0.84 [0.71, 1.01] 0.06 No 3 1041
Summary 0 0.47 0.87 [0.76, 1.00] 0.06 No Fixed 19 2228 S20
DAS28-ESR-stage IGU Refractory 0 -1.66 [-2.49, -0.83] <0.0001 Yes Fixed 1 60 S21
IGU + MTX Refractory 30 0.22 -2.42 [-2.79, -2.06] <0.00001 Yes 4 401
First-visit 0 -0.90 [-1.38, -0.42] 0.0002 Yes 1 60
Summary 85 <0.00001 -2.12 [-2.81, -1.44] <0.00001 Yes Random 5 461 S22
ACR20-stage IGU First-visit 0 1.18 [1.06, 1.30] 0.002 Yes Fixed 1 590 S21
IGU + MTX First-visit 0 0.47 1.16 [1.06, 1.27] 0.002 Yes Fixed 2 658 S22
ACR50-stage IGU + MTX First-visit 0 2.1 [1.20, 3.67] 0.009 Yes Fixed 1 60 S22
ACR70-stage IGU + MTX First-visit 0 1.6 [0.59, 4.33] 0.36 No Fixed 1 60 S22
AEs-stage IGU First-visit 0 1.26 [0.77,2.06] 0.35 No Fixed 1 590 S21
IGU + MTX Refractory 0 0.86 1.11 [0.60, 2.05] 0.74 No 5 312
First-visit 0 0.7 1.1 [0.78, 1.56] 0.58 No 3 775
Summary 0 0.96 1.1 [0.82, 1.49] 0.51 No Fixed 8 1087 S22
DAS28-ESR-age IGU Young/middle aged 0 -0.44 [-0.79,-0.09] 0.01 Yes 1 61
Elderly 0 -0.14 [-0.26,-0.02] 0.02 Yes 1 60
Summary 60 0.11 -0.24 [-0.52, 0.04] 0.09 No Random 2 121 S23
IGU + MTX Young/middle aged 73 0.05 -2.18 [-3.06,-1.31] <0.00001 Yes 2 164
Elderly 0 -1.35 [-1.47,-1.23] <0.00001 Yes 1 60
Summary 86 <0.00001 -1.84 [-2.47, -1.21] <0.00001 No Random 3 224 S25
ACR20-age IGU Young/middle aged 0 0.32 1.05 [0.79, 1.53] 0.57 No 1 80
Elderly 0 1.1 [0.79, 1.53] 0.57 No 1 60
Summary 0 0.67 1.08 [0.82, 1.42] 0.24 No Random 2 140 S23
IGU + MTX Young/middle aged 0 0.93 1.52 [1.15, 2.00] 0.003 Yes Fixed 3 241 S25
ACR50-age IGU Young/middle aged 0 0.57 0.93 [0.50, 1.72] 0.84 No 1 80
Elderly 0 1.08 [0.62, 1.89] 0.81 No 1 60
Summary 0 0.85 1.00 [0.66, 1.52] 1.00 No Fixed 2 140 S23
IGU + MTX Young/middle aged 23 0.27 1.51 [1.07, 2.12] 0.02 Yes Fixed 3 241 S25
ACR70-age IGU Young/middle aged 0 1.00 [0.35,2.84] 0.74 No 1 80
Elderly 0 0.83 [0.28,2.44] 1.00 No 1 60
Summary 0 0.97 0.92 [0.43,1.94] 0.82 No Fixed 2 140 S24
IGU + MTX Young/middle aged 0 1.83 [0.75, 4.48] 0.18 No Fixed 1 80 S25
AEs-age IGU Young/middle aged 0 0.75 [0.75,1.24] 0.27 No 1 80
Elderly 0 0.55 [0.23,1.28] 0.17 No 1 60
Summary 0 0.76 0.68 [0.43, 1.03] 0.07 No Fixed 2 140 S24
IGU + MTX Young/middle aged 0 0.64 0.95 [0.71,1.28] 0.78 No Fixed 10 887 S25
AEs IGU + MTX leukopenia 0 0.73 0.63 [0.37, 1.07] 0.09 No Fixed 10 1038 S26
LFTs 0 0.61 0.56 [0.40, 0.77] 0.0004 Yes Fixed 15 1365 S26